SYLVANT® (Siltuximab)

The FDA on April 23, 2014 approved SYLVANT® for the treatment of patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV-) -negative and human herpes virus -8 (HHV-8) -negative. SYLVANT® injection is a product of Janssen Biotech, Inc.